Adherence to Oral Therapies in Advanced Breast and Prostate Cancers

Launched by INSTITUT DE CANCÉROLOGIE DE LORRAINE · May 24, 2024

Keywords

ClinConnect Summary

This clinical trial, called AdOTAC, is studying how well patients with advanced breast and prostate cancer stick to their prescribed oral medications. The trial is currently looking to enroll 200 patients who are at least 18 years old and have been receiving oral cancer treatments for at least three months. Eligible participants include those with inoperable advanced breast cancer or prostate cancer who are being treated with specific oral therapies. Patients who are not eligible include those with early-stage cancers, those not yet on treatment for three months, or those who have a very short life expectancy.

Participants in this study will complete self-questionnaires about their treatment experience, either at the clinic on the first day or at home within ten days. Additionally, blood samples will be taken on the first day to check important health markers. This study aims to better understand how patients manage their oral therapies, which is crucial for their ongoing care. It's important to note that participants must be able to read and speak French, and they cannot be part of another clinical trial at the same time.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult over 18 years old.
• • Patient with inoperable advanced breast cancer treated with oral endocrine therapy and/or targeted therapy and patient with inoperable advanced prostate cancer treated with oral hormonal therapy and/or targeted therapy.
• • Oral anticancer medications started for at least 3 months.
• • With a performance status ≤ 3.
• • Patient has understood, signed and dated the consent form.
• • Patient covered by the social security system.
• Exclusion Criteria:
• • Patient with early breast cancer or localized prostate cancer.
• • Patient with life expectancy \< 3 months.
• • Patient in progression
• • Undergoing intravenous or oral cytotoxic chemotherapy (capecitabine, cyclophosphamide, vinorelbine).
• • Patient who has not yet started oral anticancer therapies or who has started for less than 3 months.
• • Patient unable to read or speak French.
• • Patient already included in another therapeutic trial with an experimental molecule.
• • Persons deprived of their liberty or under guardianship (including curatorship).

Trial Officials